Therapeutic Asset Ratings

1,027 results matching 1 filter

129,767 assets · 8,707 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
rc48-adc Head and Neck Squamous Cell Carcinoma	Indaptus Therapeutics, Inc	P2	B (58)
rc48-adc Rectal Carcinoma	Union Hospital, Tongji Medical College, Huazhong University of Science and Technology	P2	B (58)
rc48-adc Urothelial Carcinoma	Indaptus Therapeutics, Inc	P2	B (58)
Trastuzumab Deruxtecan Colorectal Carcinoma	Gruppo Oncologico del Nord-Ovest	P2	B (58)
Trastuzumab Deruxtecan Advanced Malignant Solid Neoplasm	National Cancer Institute (NCI)	P2	B (58)
Trastuzumab Deruxtecan Colorectal Cancer	M.D. Anderson Cancer Center	P2	B (58)
Trastuzumab Emtansine Recurrent Ovarian Carcinoma	OHSU Knight Cancer Institute	P2	B (58)
Trastuzumab Emtansine Refractory Malignant Neoplasm	OHSU Knight Cancer Institute	P2	B (58)
rc48-adc Breast Neoplasm	Pfizer	P2/3	B (58)
Zirconium Zr 89 Crefmirlimab Berdoxam Non-Small Cell Lung Carcinoma	Memorial Sloan Kettering Cancer Center	P2/3	B (58)
Immunoglobulin G1 [de-448-lysine], anti-(human epidermal growth factor receptor) (human-mouse monoclonal C225 ?1-chain) fusion protein with peptide linker (GGGGS)2 fusion protein with immunoglobulin anti-(human epidermal growth factor receptor HER3) (human clone HER3.H3 single-chain variable fragment VH-(GGGGS)3-VL), complex with human-mouse monoclonal C225 ?-chain, dimer, 214??,214???,222,222?,228,228?,231,231?-octakis(thioether) with (2S)-N-(carboxymethyl)-2-(3-mercapto-2,5-dioxo-1-pyrrolidinyl)-?-alanylglycylglycyl-L-phenylalanyl-N-[[(1S)-2-[[(1S,9S)-9-ethyl-5-fluoro-2,3,9,10,13,15-hexahydro-9-hydroxy-4-methyl-10,13-dioxo-1H,12H-benzo[de]pyrano[3?,4?:6,7]indolizino[1,2-b]quinolin-1-yl]amino]-1-methyl-2-oxoethoxy]methyl]glycinamide HR+HER2- Breast Cancer	Sichuan Baili Pharmaceutical Co., Ltd.	P3	B (57)
rc48-adc Soft Tissue Sarcoma	Gustave Roussy, Cancer Campus, Grand Paris	P3	B (57)
Brentuximab Vedotin Primary Cutaneous Lymphoma	M.D. Anderson Cancer Center	P2	B (57)
Brentuximab Vedotin Lymphatic System Disorder	UNC Lineberger Comprehensive Cancer Center	P2	B (57)
Brentuximab Vedotin Lymphomatoid Papulosis	Memorial Sloan Kettering Cancer Center	P2	B (57)
ERIBULIN/FARLETUZUMAB ANTIBODY DRUG CONJUGATE Ovarian Neoplasm	Bristol-Myers Squibb	P2	B (57)
Gemtuzumab Ozogamicin Acute Promyelocytic Leukemia	Wake Forest University Health Sciences	P2	B (57)
Inotuzumab Ozogamicin Precursor B-Cell Acute Lymphoblastic Leukemia	First Affiliated Hospital of Zhejiang University	P2	B (57)
Maridebart Cafraglutide Type 2 Diabetes Mellitus	Amgen	P2	B (57)
Polatuzumab Vedotin MALT Lymphoma	SWOG Cancer Research Network	P2	B (57)
rc48-adc Tislelizumab	Sichuan Cancer Hospital and Research Institute	P2	B (57)
rc48-adc Tumor Thrombosis	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	P2	B (57)
rc48-adc Uveal Melanoma	Grupo Español Multidisciplinar de Melanoma	P2	B (57)
Trastuzumab Deruxtecan Neoplastic Meningitis	Memorial Sloan Kettering Cancer Center	P2	B (57)
Trastuzumab Emtansine Metastatic Neoplasm	Genentech, Inc.	P2	B (57)

Showing 201 to 225 of 1,027 assets

PreviousPage 9 of 42Next